Title: Evidence for TRP Channel Sensitization in IBS with Histamine 1 Receptor Antagonism as Effective Treatment
Abstract: difference : -61.6 ± 50.8, p<0.01, and -63.3 ± 43.1, p<0.01, respectively).No significant differences in the placebo group compared to baseline were observed, and neither between treatment and placebo.The GSRS-IBS total score significantly decreased for both the treatment and the placebo group 2 weeks after FMT (-0.46 ± 0.32, p<0.01, and -0.71 ± 0.73, p<0.05, respectively) and 4 weeks after FMT compared to baseline (-0.79 ± 0.57, p<0.01, and -0.57± 0.63, p<0.05, respectively).Again, no differences between the two intervention groups were observed.The IBS-QoL total score was significantly increased in the treatment but not in the placebo group at 8 weeks (10.0 ± 6.3, p<0.01).Similar results were observed in three out of eight SF-36 subscores, especially in the general health subscore.This score was significantly increased in the treatment compared to the placebo group 8 weeks after p<0.01).Conclusions These data showed that there is a beneficial effect of FMT on symptom scores and quality of life in IBS patients.This effect is also observed in the placebo group, although to a lesser extent, indicating that placebo-controlled studies are essential in IBS patients.The bowel cleansing and the processing of the autologous fecal material might have contributed to the placebo effect.Further analysis on individual basis, separation into non-responders and responders as well as correlation with additional outcomes such as microbiota composition will provide more insight.
Publication Year: 2017
Publication Date: 2017-04-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot